Calls Now Open
2024 ADDF-Harrington + 2025 Harrington Scholar-Innovator Programs
April 16, 2024
Harrington Discovery Institute at University Hospitals in Cleveland, Ohio, today announced the 2024 class of Harrington Scholar-Innovators. The scholar awards will support breakthrough new treatments for heart disease, autoimmune disorders, cancer, infectious disease, inflammation, and rare diseases using small molecule...
Continue ReadingDecember 14, 2016
Cleveland, Ohio – 2016 Harrington Fellows have been selected by Harrington Discovery Institute. The new Harrington Fellows Award recognizes promising early- to mid-career physician-scientists in the greater Cleveland medical community and provides $75,000 per year for two years to support their research efforts.Harrington... Continue Reading
October 17, 2016
Cleveland, Ohio – Mukesh K. Jain, MD, University Hospitals Chief Scientific Officer, has been elected to the National Academy of Medicine, joining a distinguished organization that has made important contributions to health, medicine and science. This honor underscores Dr. Jain’s role in helping shape research and health... Continue Reading
August 15, 2016
Cleveland – The Trustees of the Burton D. Morgan Foundation in Hudson Ohio have awarded a grant of $200,000 to the Harrington Discovery Institute at University Hospitals in Cleveland, Ohio to support the Institute’s Innovation Support Center (ISC) and its mission of mentoring physician-scientists to advance novel... Continue Reading
June 13, 2016
LONDON AND CLEVELAND, OHIO, JUNE 13, 2016: Arix Bioscience Limited (Arix Bioscience), a global healthcare and life science company supporting medical innovation, announced today it has provided development capital to OptiKira, LLC (OptiKira), an early stage company developing drugs to help prevent blindness.Extensive research... Continue Reading
June 06, 2016
When the Lauder family founded the Alzheimer’s Drug Discovery Foundation (ADDF) in 1998, they knew that proprietary boundaries would only limit efforts to develop effective Alzheimer’s drugs. So they resolved to make the ADDF’s knowledge available to everyone working to overcome this devastating disease—and all the... Continue Reading
May 02, 2016
CLEVELAND AND INDIANAPOLIS – May 2, 2016 – BioMotiv, a drug development accelerator associated with the Harrington Project, and Indiana University Research and Technology Corp. announce the formation of a new biotechnology start-up, Allinaire Therapeutics. Allinaire Therapeutics aims to develop novel therapeutics for... Continue Reading
April 18, 2016
LONDON, APRIL 18, 2016: - Arix Bioscience Limited (Arix Bioscience), formerly Perceptive Bioscience Investments Limited, a global healthcare and life science company supporting medical innovation, announced today it has agreed to provide up to $25 million capital to BioMotiv LLC, a US-based therapeutic accelerator organization... Continue Reading
April 13, 2016
WILMINGTON, MA, April 13, 2016 – Charles River Laboratories International, Inc. (NYSE: CRL) today announced that it has entered into a strategic partnership with BioMotiv, LLC, the therapeutic accelerator company associated with The Harrington Project for Discovery & Development. Through this partnership, Charles River will... Continue Reading
March 15, 2016
CLEVELAND – The third annual Harrington Prize for Innovation in Medicine has been awarded to Jeffrey M. Friedman, MD, PhD, of The Rockefeller University, New York City, for his discovery of leptin and the leptin-mediated pathway that controls feeding behavior.The Harrington Prize for Innovation in Medicine, established in... Continue Reading
February 29, 2016
Formed by BioMotiv and Rutgers UniversityCLEVELAND AND NEW BRUNSWICK— FEBRUARY 29, 2016— BioMotiv, a drug development accelerator associated with The Harrington Project, and Rutgers, the State University of New Jersey, are announcing the formation of a new biotechnology startup, Z53 Therapeutics. Z53 Therapeutics aims to... Continue Reading